|
|
Post by kc on May 18, 2017 11:24:44 GMT -5
Need to get this topic started and its actually a novel idea. I think it had been discussed a long time ago. But since it was brought up today. Lets explore it.
We can start with an article from Afrezza user Mike Hoskins who is with Diabetes Mine publication Healthline from June 6th, 2012.
FDA to OK Insulin Without a Prescription? Or...?
www.healthline.com/diabetesmine/fda-to-ok-insulin-without-a-prescription-or
With a Paradigm shift on how to market Afrezza direct to the consumer we will be picking a big fight with the establishment Big Pharma's who love pushing their high cost expensive products. They have the power and market with the Doctors both the GP and Endo market. So it will be an uphill battle but a very interesting one as Consumers need better care and access that perhaps MannKind and Amazon might be able to offer. You want to get picked off by a big Pharma then you wage a war on pricing insulin direct to the consumer with easy access and helping that diabetic to be responsible for their own outcome.
USA today article from 2012 on this same topic.
usatoday30.usatoday.com/news/health/story/health/story/2012-03-08/FDA-considers-waiving-prescriptions-for-key-drugs/53416812/1
|
|
|
|
Post by kc on May 20, 2017 8:45:28 GMT -5
If you read this article carefully you will see why MannKind has focused their re-launch and future advertising campaign to empower people with diabetes. Diabetic patients are no longer passive participants to seeing their lives improved. They now search out and seek ways to make living with type one and type two diabetes easier. The big three insulin producers really don't do a lot to help the diabetic take charge of their own treatment. MannKind with their revolutionary disruptive treatment product Afrezza it's just the paradigm shift that younger patients want. Don't count this company dead yet as I believe they are going down the right path. The information they rolled out at their annual shareholders meeting fits this story on a type one diabetes blog. Read it,and see if you don't agree. beyondtype1.org/how-to-engage-young-adults-with-type-1-diabetes-a-new-study/HOW TO ENGAGE YOUNG ADULTS WITH TYPE 1 DIABETES: A NEW STUDY WRITTEN BY: Katie Doyle FacebookTwitterEmail Type 1 diabetes affects the mental wellbeing of everyone living with it, and this can be particularly challenging for young people who are also learning the essential lessons of self-care for adulthood. A recent study by the National University of Ireland (NUI), Galway, indicated that there is “a lack of high-quality, well-designed interventions, aimed at improving health outcomes for young adults with Type 1 diabetes.” This study, called D1 now, is significant because, according to the researchers, it’s one of the first to examine “interventions,” or solutions, and the role they play in ensuring that young adults have the best possible outcomes in their independent diabetes management. The Galway-based team, with a network of stakeholders across Ireland, the UK and beyond, found in the D1 now study that young adults are the driving force behind change in diabetes care and that healthcare providers need to change the way they work with young adults. Since 2014, the D1 now researchers have worked with Galway University Hospitals to examine how young adults interact with their diabetes teams and how consistently they attend appointments to figure out ways to improve the diabetes management and overall health of these patients. Along the way, D1 now has also come up with new ways to engage with the Type 1 community. The Strength in Numbers (SIN) Conference, held in June 2016, was a three-day international symposium targeting young adults and their engagement in their own diabetes management to result in better outcomes. A Young Adult Panel, a key part of the research, was consulted during the planning of the SIN conference and one of the highlights of the event: a Hackathon to brainstorm ways to use technology to support young adults with Type 1. The Young Adult Panel offered opportunities for engagement with the local Type 1 community. Gertruda Ceburntyne, a 20-year-old Biomedical Science major in Galway and member of the Young Adult Panel, says, “Before I joined the Young Adult Panel, I didn’t know any fellow young people with diabetes. I felt like going to the diabetes clinic was like going into an exam. After meeting new people and hearing about what worries they have and how they cope with Type 1, it is much easier to go to an appointment with the diabetes clinic knowing that there are other people in a similar boat.” Lisa Hynes, currently a postdoctoral researcher at West Virginia University, was part of the organizing team for the conference while working on the D1 now study. This event brought together stakeholders in the diabetes community to “give feedback on our work and produce [an intervention] to improve self-management among young adults with Type 1 diabetes in Galway,” Lisa says. “Because young adults are experiencing so much change, they rely a lot on the support and information they get from diabetes service providers. Unfortunately, the diabetes clinic is a busy place, where young adults don’t always meet the same service provider. It seems to me that service providers really know what kind of service they would like to provide to young adults but they are limited because they are so busy and can struggle to get to know young adults during appointments.” To find out more from a young adult who is at the receiving end of these visits, I posed a question to the Young Adult Panel: What should healthcare providers keep in mind when working with young adults with Type 1? Gertruda shares that empathy is critical. “First and foremost, they need to keep in mind that unless they themselves have Type 1 diabetes, they will never know how difficult it is, living with the illness. They need to put themselves in the shoes of a young adult with Type 1 and understand how much of an inconvenience it is to have this constant pressure to worry about your health.” Aoife Gannon has had Type 1 for 15 years. Her response was that diabetes care teams need to connect with patients: “People with Type 1 aren’t computers or robots. They are people who genuinely want to get on with life. I think [healthcare professionals] need to brainstorm or generate ideas to help motivate people and understand where we’re coming from.” Aoife also participated in the Hackathon, which she describes as “a gathering where programmers collaboratively code in an extreme manner over a short period of time. We were split into groups of twos [according to] age and topic” to come up with technology solutions to reach young adults with Type 1. The four fresh ideas included a Transition App to help ease the switch from pediatric to adult care; an Insulin, Pumps, Understanding and Management (IPSUM) app for patients and providers to share information; SnapD1, a Snapchat channel with motivating social media content; and DiaLog, an app for patients to connect and share their experiences with diabetes teams when connected to hospital wifi. SnapD1 took home the prize for Best Pitch Award, and the results of the event were felt almost immediately among young adults with Type 1 who were involved. Cameron Keighron, a 22-year-old recent university graduate, describes the excitement he felt leading up to the SIN Conference: “It was the culmination of two years of our work. Young adults were going to be heard and listened to about their diabetes management. We were about to lead the way in diabetes research in Ireland for young adults [with Type 1].” Afterward, Cameron says, “I felt invigorated, I felt that I could make a real difference to diabetes care and wanted to continue this. We had all put a lot of work into the previous two years and the conference being such a success was really rewarding. I learned a lot about disseminating research as well as the importance of patient involvement. I learned about the importance of breaking down perceived barriers and reducing the amount of jargon used when trying to make a difference in the healthcare of Young Adults. I also improved my own public speaking and networking skills.” Aoife left feeling that patients, as well as healthcare teams, need to think outside the box in terms of their own diabetes management. “We need to understand that if we open up to them, they can be our helpers. It is a difficult barrier to overcome.” What are the next steps for the D1 now study? Lisa Hynes is hopeful about positive developments coming up: “We recently received funding from the Health Research Board in Ireland to move onto the next phase of the research. In this, we will roll out a pilot intervention that was developed during the work we’ve already completed, to find out if people will like it, if it’s possible to implement it in busy diabetes clinics, and if it can achieve the aim of improving young adult diabetes self-management. We are working with a fantastic team of collaborators from Ireland, the U.K., and beyond to complete this work, so who knows how far this can go?!” Keep up with the D1Now project on Facebook and Twitter. REFERENCES HYNES, L., O’HARA, M.C., JORDAN, V., HUTCHINSON, O.C., O’DEA, F., BYRNE, M., & DINNEEN, S.F. (2016). STRENGTH IN NUMBERS HACKATHON: USING A NOVEL TECHNOLOGY-FOCUSED BRAINSTORMING ACTIVITY TO ENGAGE STAKEHOLDERS IN INTERVENTION DEVELOPMENT. THE EUROPEAN HEALTH PSYCHOLOGIST, 18, 6, PP. 287-293. MC O’ HARA, L HYNES, M O’DONNELL, N NERY, M BYRNE, SR HELLER AND SF DINNEEN, FOR THE IRISH TYPE 1 DIABETES YOUNG ADULT STUDY GROUP. A SYSTEMATIC REVIEW OF INTERVENTIONS TO IMPROVE OUTCOMES FOR YOUNG ADULTS WITH TYPE 1 DIABETES: TOWARDS THE DEVELOPMENT OF A NEW INTERVENTION. DIABETIC MEDICINE, [EPUB AHEAD OF PRINT], 20 OCT 2016, DOI: 10.1111/DME.13276 O’HARA, M.C. “EXPERIENCES OF PATIENT INVOLVEMENT IN THE DEVELOPMENT OF AN INTERVENTION FOR YOUNG ADULTS WITH T1D: THE D1 NOW STUDY.” NUIG HEALTH PSYCHOLOGY BLOG. 14 NOVEMBER 2016. |
|
|
|
Post by mnholdem on May 20, 2017 9:43:55 GMT -5
When former CEO Chris Vehrbacher was running Sanofi with Pascale Witz, head of their diabetes division, he presented a 3-year plan to engage patients in treating diabetes. Ms. Witz was planning to create a patient advocacy committee that would consist of diabetes patients and medical KOLs to better communicate patient needs with Sanofi leadership. Chris was fired by the Sanofi BoD and Pascale quit shortly thereafter.
For decades, the pharmaceutical companies have arrogantly dictated what patients need. I think that MannKind Corporation, together with OneDrop, are blazing a new trail into the diabetes treatment industry and they (and shareholders) will be handsomely rewarded for their vision and determination.
|
|
|
|
Post by ssiegel on May 20, 2017 10:14:50 GMT -5
When former CEO Chris Vehrbacher was running Sanofi with Pascale Witz, head of their diabetes division, he presented a 3-year plan to engage patients in treating diabetes. Ms. Witz was planning to create a patient advocacy committee that would consist of diabetes patients and medical KOLs to better communicate patient needs with Sanofi leadership. Chris was fired by the Sanofi BoD and Pascale quit shortly thereafter. For decades, the pharmaceutical companies have arrogantly dictated what patients need. I think that MannKind Corporation, together with OneDrop, are blazing a new trail into the diabetes treatment industry and they (and shareholders) will be handsomely rewarded for their vision and determination. I recall MNKD announcing after SNY left that it too was planning "a patient advocacy committee that would consist of diabetes patients and medical KOLs." What happened to it? |
|
|
|
Post by peppy on May 20, 2017 10:21:48 GMT -5
When former CEO Chris Vehrbacher was running Sanofi with Pascale Witz, head of their diabetes division, he presented a 3-year plan to engage patients in treating diabetes. Ms. Witz was planning to create a patient advocacy committee that would consist of diabetes patients and medical KOLs to better communicate patient needs with Sanofi leadership. Chris was fired by the Sanofi BoD and Pascale quit shortly thereafter. For decades, the pharmaceutical companies have arrogantly dictated what patients need. I think that MannKind Corporation, together with OneDrop, are blazing a new trail into the diabetes treatment industry and they (and shareholders) will be handsomely rewarded for their vision and determination. agreed. Interesting if an Amazon affiliation could be made. heh
|
|
|
|
Post by peppy on May 20, 2017 10:31:09 GMT -5
If you read this article carefully you will see why MannKind has focused their re-launch and future advertising campaign to empower people with diabetes. Diabetic patients are no longer passive participants to seeing their lives improved. They now search out and seek ways to make living with type one and type two diabetes easier. The big three insulin producers really don't do a lot to help the diabetic take charge of their own treatment. MannKind with their revolutionary disruptive treatment product Afrezza it's just the paradigm shift that younger patients want. Don't count this company dead yet as I believe they are going down the right path. The information they rolled out at their annual shareholders meeting fits this story on a type one diabetes blog. Read it,and see if you don't agree. beyondtype1.org/how-to-engage-young-adults-with-type-1-diabetes-a-new-study/HOW TO ENGAGE YOUNG ADULTS WITH TYPE 1 DIABETES: A NEW STUDY WRITTEN BY: Katie Doyle FacebookTwitterEmail Type 1 diabetes affects the mental wellbeing of everyone living with it, and this can be particularly challenging for young people who are also learning the essential lessons of self-care for adulthood. A recent study by the National University of Ireland (NUI), Galway, indicated that there is “a lack of high-quality, well-designed interventions, aimed at improving health outcomes for young adults with Type 1 diabetes.” This study, called D1 now, is significant because, according to the researchers, it’s one of the first to examine “interventions,” or solutions, and the role they play in ensuring that young adults have the best possible outcomes in their independent diabetes management. The Galway-based team, with a network of stakeholders across Ireland, the UK and beyond, found in the D1 now study that young adults are the driving force behind change in diabetes care and that healthcare providers need to change the way they work with young adults. Since 2014, the D1 now researchers have worked with Galway University Hospitals to examine how young adults interact with their diabetes teams and how consistently they attend appointments to figure out ways to improve the diabetes management and overall health of these patients. Along the way, D1 now has also come up with new ways to engage with the Type 1 community. The Strength in Numbers (SIN) Conference, held in June 2016, was a three-day international symposium targeting young adults and their engagement in their own diabetes management to result in better outcomes. A Young Adult Panel, a key part of the research, was consulted during the planning of the SIN conference and one of the highlights of the event: a Hackathon to brainstorm ways to use technology to support young adults with Type 1. The Young Adult Panel offered opportunities for engagement with the local Type 1 community. Gertruda Ceburntyne, a 20-year-old Biomedical Science major in Galway and member of the Young Adult Panel, says, “Before I joined the Young Adult Panel, I didn’t know any fellow young people with diabetes. I felt like going to the diabetes clinic was like going into an exam. After meeting new people and hearing about what worries they have and how they cope with Type 1, it is much easier to go to an appointment with the diabetes clinic knowing that there are other people in a similar boat.” Lisa Hynes, currently a postdoctoral researcher at West Virginia University, was part of the organizing team for the conference while working on the D1 now study. This event brought together stakeholders in the diabetes community to “give feedback on our work and produce [an intervention] to improve self-management among young adults with Type 1 diabetes in Galway,” Lisa says. “Because young adults are experiencing so much change, they rely a lot on the support and information they get from diabetes service providers. Unfortunately, the diabetes clinic is a busy place, where young adults don’t always meet the same service provider. It seems to me that service providers really know what kind of service they would like to provide to young adults but they are limited because they are so busy and can struggle to get to know young adults during appointments.” To find out more from a young adult who is at the receiving end of these visits, I posed a question to the Young Adult Panel: What should healthcare providers keep in mind when working with young adults with Type 1? Gertruda shares that empathy is critical. “First and foremost, they need to keep in mind that unless they themselves have Type 1 diabetes, they will never know how difficult it is, living with the illness. They need to put themselves in the shoes of a young adult with Type 1 and understand how much of an inconvenience it is to have this constant pressure to worry about your health.” Aoife Gannon has had Type 1 for 15 years. Her response was that diabetes care teams need to connect with patients: “People with Type 1 aren’t computers or robots. They are people who genuinely want to get on with life. I think [healthcare professionals] need to brainstorm or generate ideas to help motivate people and understand where we’re coming from.” Aoife also participated in the Hackathon, which she describes as “a gathering where programmers collaboratively code in an extreme manner over a short period of time. We were split into groups of twos [according to] age and topic” to come up with technology solutions to reach young adults with Type 1. The four fresh ideas included a Transition App to help ease the switch from pediatric to adult care; an Insulin, Pumps, Understanding and Management (IPSUM) app for patients and providers to share information; SnapD1, a Snapchat channel with motivating social media content; and DiaLog, an app for patients to connect and share their experiences with diabetes teams when connected to hospital wifi.SnapD1 took home the prize for Best Pitch Award, and the results of the event were felt almost immediately among young adults with Type 1 who were involved. Cameron Keighron, a 22-year-old recent university graduate, describes the excitement he felt leading up to the SIN Conference: “It was the culmination of two years of our work. Young adults were going to be heard and listened to about their diabetes management. We were about to lead the way in diabetes research in Ireland for young adults [with Type 1].” Afterward, Cameron says, “I felt invigorated, I felt that I could make a real difference to diabetes care and wanted to continue this. We had all put a lot of work into the previous two years and the conference being such a success was really rewarding. I learned a lot about disseminating research as well as the importance of patient involvement. I learned about the importance of breaking down perceived barriers and reducing the amount of jargon used when trying to make a difference in the healthcare of Young Adults. I also improved my own public speaking and networking skills.” Aoife left feeling that patients, as well as healthcare teams, need to think outside the box in terms of their own diabetes management. “We need to understand that if we open up to them, they can be our helpers. It is a difficult barrier to overcome.” What are the next steps for the D1 now study? Lisa Hynes is hopeful about positive developments coming up: “We recently received funding from the Health Research Board in Ireland to move onto the next phase of the research. In this, we will roll out a pilot intervention that was developed during the work we’ve already completed, to find out if people will like it, if it’s possible to implement it in busy diabetes clinics, and if it can achieve the aim of improving young adult diabetes self-management. We are working with a fantastic team of collaborators from Ireland, the U.K., and beyond to complete this work, so who knows how far this can go?!” Keep up with the D1Now project on Facebook and Twitter. to come up with technology solutions to reach young adults with Type 1. The four fresh ideas included a Transition App to help ease the switch from pediatric to adult care; an Insulin, Pumps, Understanding and Management (IPSUM) app for patients and providers to share information; SnapD1, a Snapchat channel with motivating social media content; and DiaLog, an app for patients to connect and share their experiences with diabetes teams when connected to hospital wifi.
I hope snapD1 chat will have an afrezza presence. Maybe included in the Insulin, understanding and management. The Pediatric trial around the corner.
|
|
|
|
Post by cyn on May 20, 2017 12:15:11 GMT -5
Reaching out directly to the "Tech Savy" Millennials thru innovative Apps and Networking resources is absolutely brilliant and MNKD is right on target in doing so! Millennials don't trust the "Mega" Corps (i.e. Big Pharm) who for decades have controlled and ramrodded all Diabetic treatment options for them ... of course, with the assistance of many complacent, blinded-sided US Endos. Millennials demand choices and are magnets toward "out of the box" thinking and approaches to treatment. They don't easily drink the party-line Kool-Aid, especially from Big Corps. "Former" Sanofi leadership was smart to identify with this fast growing T1 niche market when they first partnered with MNKD. However, when the going got tough, Sanofi coward and retreated back to their old arrogant drug delivery tactics and "Big Pharma" thinking. Sanofi chose to just walk away upon the first signs of stormy weather (i.e lackluster Afrezza sales) versus making any course corrections to their marketing plan. Now with growing technology, information sharing, and innovative distribution/marketing options, small corporations like MNKD are becoming empowered in finding ways to go around Big Pharma. This is all good stuff and many kudos go out to MNKD for sticking to their guns and thinking outside the box. Imo, if MNKD can demonstrate "any amount" of positive traction in gaining market share in this fast growing Millennial T1 market, especially internationally, it's off to the races.
|
|
|
|
Post by lakon on May 20, 2017 12:28:16 GMT -5
When former CEO Chris Vehrbacher was running Sanofi with Pascale Witz, head of their diabetes division, he presented a 3-year plan to engage patients in treating diabetes. Ms. Witz was planning to create a patient advocacy committee that would consist of diabetes patients and medical KOLs to better communicate patient needs with Sanofi leadership. Chris was fired by the Sanofi BoD and Pascale quit shortly thereafter. For decades, the pharmaceutical companies have arrogantly dictated what patients need. I think that MannKind Corporation, together with OneDrop, are blazing a new trail into the diabetes treatment industry and they (and shareholders) will be handsomely rewarded for their vision and determination. The combination with a mobile phone is priceless. It opens the door to direct and indirect communications with a network effect. Tie in with social networking, support groups, patient advocacy, finance, insurance, payments, medical advice, prescriptions, teledoc, ..., and you have an ECOSYSTEM OF CHANGE that is truly CHEAPER, FASTER, and BETTER. (Cut out the middleman. Plain and simple.)  |
|
|
|
Post by boytroy88 on May 20, 2017 12:45:40 GMT -5
When former CEO Chris Vehrbacher was running Sanofi with Pascale Witz, head of their diabetes division, he presented a 3-year plan to engage patients in treating diabetes. Ms. Witz was planning to create a patient advocacy committee that would consist of diabetes patients and medical KOLs to better communicate patient needs with Sanofi leadership. Chris was fired by the Sanofi BoD and Pascale quit shortly thereafter. For decades, the pharmaceutical companies have arrogantly dictated what patients need. I think that MannKind Corporation, together with OneDrop, are blazing a new trail into the diabetes treatment industry and they (and shareholders) will be handsomely rewarded for their vision and determination. The combination with a mobile phone is priceless. It opens the door to direct and indirect communications with a network effect. Tie in with social networking, support groups, patient advocacy, finance, insurance, payments, medical advice, prescriptions, teledoc, ..., and you have an ECOSYSTEM OF CHANGE that is truly CHEAPER, FASTER, and BETTER. (Cut out the middleman. Plain and simple.) You can bet the BPs are going to fight this tooth and nails...along with the "middleman"....should be interesting...hope I'm on the "right" side even though I know I'm on the *right* side...LOL |
|
|
|
Post by mnholdem on May 20, 2017 13:02:24 GMT -5
I think that giant pharmaceutical companies have worn out their welcome in this country, but the myriad of rules and regulations enacted by former U.S. Congresses and Executive Administrations for decades have stifled a free market economy and enabled BPs and BPMs to rake in enormous profits at the expense of families who are force to pay an unacceptably high price for drugs. Behemoths like Amazon and Apple may pull off what our government has either been too corrupt or too inept to accomplish - an entirely new low cost healthcare system. I am not making a political statement, but simply observing that the current Administration's goal of streamlining, simplifying and modernizing FDA requirements could open the door to an entirely new model of health care system in the USA. Amazon, like Apple, has enormous resources to cut out the middle man and drive down costs. Insurance companies, hospitals and patient advocates will fully endorse this new system for delivering lowest-priced drugs. PBMs may be on the way out. Perhaps MannKind will one day be commended for recognizing change and leading the way in defiance of an antiquated and ineffective system.  |
|
|
|
Post by cyn on May 20, 2017 20:31:43 GMT -5
mnholdem writes... "I think that giant pharmaceutical companies have worn out their welcome in this country, but the myriad of rules and regulations enacted by former U.S. Congresses and Executive Administrations for decades have stifled a free market economy and enabled BPs and BPMs to rake in enormous profits at the expense of families who are force to pay an unacceptably high price for drugs."
Totally agree and this is why MNKD must focus on penetrating foreign markets ASAP. Given the epidemic growth in diabetes among young UAE millennials, if MNKD can secure a footprint in this region then other regions will follow, including the US. JMHO
|
|
|
|
Post by audiomr on May 22, 2017 11:58:28 GMT -5
mnholdem writes... "I think that giant pharmaceutical companies have worn out their welcome in this country, but the myriad of rules and regulations enacted by former U.S. Congresses and Executive Administrations for decades have stifled a free market economy and enabled BPs and BPMs to rake in enormous profits at the expense of families who are force to pay an unacceptably high price for drugs." Totally agree and this is why MNKD must focus on penetrating foreign markets ASAP. Given the epidemic growth in diabetes among young UAE millennials, if MNKD can secure a footprint in this region then other regions will follow, including the US. JMHO The thinking here seems inverted. The reason pharmas can charge so much in the U.S. is that health care here is fragmented and relatively lightly regulated in terms of pricing, plus DTC marketing is permitted. That makes the U.S. the best drug market in the world. In most developed countries, the government has a strong hand in negotiating drug prices (something U.S. laws essentially forbid), and they just won't pay the prices charged here. Although international expansion certainly would be good for Mannkind, margins will be lower than they are here, and there will be initial costs associated with obtaining approvals. Nor is there any reason to think that gaining market share will be any easier outside the U.S. America first really is a good motto in this instance. |
|
|
|
Post by babaoriley on May 22, 2017 12:23:12 GMT -5
I think that giant pharmaceutical companies have worn out their welcome in this country, but the myriad of rules and regulations enacted by former U.S. Congresses and Executive Administrations for decades have stifled a free market economy and enabled BPs and BPMs to rake in enormous profits at the expense of families who are force to pay an unacceptably high price for drugs. Behemoths like Amazon and Apple may pull off what our government has either been too corrupt or too inept to accomplish - an entirely new low cost healthcare system. I am not making a political statement, but simply observing that the current Administration's goal of streamlining, simplifying and modernizing FDA requirements could open the door to an entirely new model of health care system in the USA. Amazon, like Apple, has enormous resources to cut out the middle man and drive down costs. Insurance companies, hospitals and patient advocates will fully endorse this new system for delivering lowest-priced drugs. PBMs may be on the way out. Perhaps MannKind will one day be commended for recognizing change and leading the way in defiance of an antiquated and ineffective system. All I can say is this rally in share price has brought out the "Victor Laszlo" in MN!! "This time our side will win." |
|
|
|
Post by mnholdem on May 22, 2017 18:34:19 GMT -5
Indeed I do occasionally find myself saying, "MannKind, this could be the beginning of a beautiful friendship". Although, come to think of it, those were the words of Rick Blaine, who helped the resistance leader Victor Laszlo to escape. Close enough, IMO.
|
|
|
|
Post by boca1girl on May 23, 2017 6:28:00 GMT -5
|
|
